Immunocore (NASDAQ:IMCR) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Immunocore (NASDAQ:IMCR) issued its quarterly earnings data on Thursday. The company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01), FiscalAI reports. The business had revenue of $115.93 million for the quarter, compared to the consensus estimate of $148.47 million. Immunocore had a negative net margin of 6.68% and a negative return on equity of 7.07%.

Here are the key takeaways from Immunocore’s conference call:

• Positive Sentiment: KIMMTRAK first-half net revenue rose 16% year over year to $223 million, including $116 million in Q2, supported by continued U.S. community demand and penetration above 70% in major markets.
• Positive Sentiment: Five-year data showed KIMMTRAK doubled the likelihood of survival at five years versus investigator’s choice in HLA-A2-positive metastatic uveal melanoma, with overall survival of 16% versus 8%.
• Positive Sentiment: Enrollment in the pivotal TEBE-AM trial for previously treated advanced cutaneous melanoma is nearly complete, with headline overall-survival data potentially available by year-end 2026; ATOM and PRISM-MEL-301 also continue to advance.
• Neutral Sentiment: Immunocore expects first-patient dosing of its type 1 diabetes candidate in the coming weeks, plans to submit a CTA for a second autoimmune candidate by year-end, and expects updated HIV data in the first half of 2027.
• Negative Sentiment: Q2 U.S. sales benefited from approximately $6 million of distributor inventory stocking, creating a headwind for Q3, while the company expects roughly $120 million in sales-related rebate payments during the second half of 2026.

Immunocore Price Performance

NASDAQ IMCR traded up $1.21 on Thursday, reaching $34.50. The company had a trading volume of 572,933 shares, compared to its average volume of 549,982. Immunocore has a 12 month low of $27.56 and a 12 month high of $40.71. The company has a quick ratio of 4.15, a current ratio of 4.18 and a debt-to-equity ratio of 1.00. The firm’s 50 day moving average price is $31.54 and its 200 day moving average price is $31.33. The stock has a market capitalization of $1.76 billion, a PE ratio of -62.73 and a beta of 0.74.

Analyst Upgrades and Downgrades

Several research firms have issued reports on IMCR. Zacks Research lowered Immunocore from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a research note on Friday, July 17th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunocore in a research report on Monday, July 13th. Mizuho boosted their price objective on Immunocore from $34.00 to $35.00 and gave the company a “neutral” rating in a research note on Monday. Finally, HC Wainwright reissued a “buy” rating and issued a $100.00 target price on shares of Immunocore in a report on Monday, April 20th. Five analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $56.29.

Institutional Investors Weigh In On Immunocore

A number of hedge funds have recently bought and sold shares of IMCR. Arax Advisory Partners grew its stake in shares of Immunocore by 302.9% in the 4th quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock worth $48,000 after buying an additional 1,042 shares in the last quarter. Osaic Holdings Inc. increased its holdings in shares of Immunocore by 117.4% in the 2nd quarter. Osaic Holdings Inc. now owns 3,148 shares of the company’s stock worth $97,000 after buying an additional 1,700 shares during the last quarter. State of Tennessee Department of Treasury purchased a new stake in shares of Immunocore during the 2nd quarter valued at about $132,000. Federation des caisses Desjardins du Quebec raised its position in shares of Immunocore by 162.1% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 5,478 shares of the company’s stock valued at $190,000 after buying an additional 3,388 shares in the last quarter. Finally, Cetera Investment Advisers bought a new position in shares of Immunocore in the 4th quarter valued at about $203,000. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.